At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
AZD5718 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)
In Brief
A Phase 2 clinical trial evaluating AZD5718 and Placebo for Coronary Artery Disease. Completed, enrolled 129 participants across 9 sites in 3 countries.
Detailed Summary
This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries. Approximately 138 CAD patients will be randomized to AZD5718 or placebo (treatment duration 12 weeks).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesDenmark, Finland, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartOct 2017
Primary CompletionApr 2020
TodayJul 2026
First PostedOct 23, 2017
Enrollment StartOct 30, 2017
Primary CompletionApr 8, 2020
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.7 years ago
Interventions
AZD5718drug
Oral dose of AZD5718 (tablet)
AZD5718drug
Oral dose of AZD5718 (tablet)
Placebodrug
Matching placebo (tablet)